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Abstract
In adult rats, high doses of methamphetarnine (METH) and phencyclidine (PCP)
produce neurological damage in the central nervous system and subsequent
behavioral deficits. These deficits are thought to be due to changes in the
neurotransmitter systems, such as dopamine, serotonin, and glutamate. Studies have
suggested that exposure to METH and PCP during early development produces
behavioral deficits. However, it is unclear if exposure to these drugs during later
development also produces similar behavioral deficits.
The present study examined the effects of brief exposure to METH and PCP
during later development and subsequent changes in behavior. Rats on postnatal days
50-51 were exposed to METH and PCP. To measure short- and long-term effects of
drugs on behavior three experiments were conducted using different behavioral tests:
locomotor activity, social interaction, and spatial learning. Rats were housed together
in a gang cage fro!Il postnatal day (PD) 30 until PD80. Oh PD 80, rats were housed
individually in single cages shortly prior to the learning experiment, which involved

food-deprivation. Experiment I: Locomotor activity was measured during the acute
drug sate and the withdrawal period. On PD 50-51, rats received METH (9 mg/kg),
PCP (9 mg/kg), or saline. A total of four injections were done subcutaneously at a 12
hr interval (twice/day, 2 days). Using a video-tracking system locomotor activity was

tested in an open field arena for 60 min at multiple times: acute state (immediately
after the first and the third injection) and withdrawal state (3, 7, 14 and 28 days after
the last injection). The first METH iajection enhanced locomotion during the first
half of the session, but not the second half, whereas the third injection of METH did
not affect locomotion during the entire session. The first PCP injection did not affect
locomotion during the first half of the session, but increased locomotion during the
second half, whereas the third injection of PCP further enhanced locomotion during
the entire session. Locomotor activity of METH and PCP groups was comparable to
that of vehicle group after withdrawal Day 3. Experiment 2: Social interaction was
measured during the withdrawal period. The schedule of METH and PCP treatment
(age of rats, dose, frequency, interval, and mode) was identical to Experiment I.
Social interaction was measured by the frequency and the duration of the contact
during a 60 min period. METH-treated rats showed a gradual decrease in social
interaction on Day 7-14 of withdrawal. PCP-treated rats showed a decreasing trend in
social interaction during the initial contact, the first 8 min observation period.
Experiment 3: Spatial and reversal learning were measured in adulthood, after PD 90.
The schedule of METH and PCP treatment (age of rats, dose, frequency, interval, and
mode) was identical to Experiment I and 2. To test.spatial learning, rats were trained

in a spatial discrimination task, which required a barpress opposite to the cue location
to receive a food pellet. Once their performance reached a criterion (?_85% correct
responses, 3 sessions), rats were trained in the reversal task, which required a barpress
same as the cue location. Neither METH nor PCP affected spatial discrimination.
During reversal, however, METH-treated rats tended to show a retarded acquisition,
whereas PCP significantly impaired reversal learning.
The present study demonstrates that exposure to METH and PCP on PDS0-51
affected locomotor activity during the acute drug phase but not during withdrawal.
However, METH and PCP during later development decreased social interaction
during the withdrawal period, and selectively impaired reversal learning in adulthood.
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I

Exposure to Methamphetamine and Phencyclidine during Development
and Subsequent Behavioral Change

Methamphetamine (METH) is an amphetamine derivative, which enhances
dopamine (DA) transmission in the brain. Phencyclidine (PCP) is a glutamate
antagonist, which blocks N-methyl-D-aspartate (NMDA) receptors in the central
nervous system (Zukin & Javitt, 1993). Despite their action on different
neurotransmitter systems, methamphetamine and PCP appear to produce similar
behavioral changes acutely and chronically. Such behavioral changes differ
characteristically during acute and chronic states and also differ depending on the
doses tested. For example, METH affects spontaneous locomotion (Clemens et al.,
2004) and produces neurotoxic effects at high doses by depleting DA and serotonin
(5-HT) in several brain regions, including the striatum, the nucleus accumbens, and
the prefrontal cortex (Friedman et al., 1998; Gehrke et al., 2003). Repeated METH
administration leads to long-term behavioral and neurochemical changes with a
decrease in DA and 5-HT and their metabolites in the brain, while chronic PCP results
in upregulation ofNMDA receptors in limbic regions, such as the prefrontal cortex
and the hippocampus (Bisagno et al., 2002; Friedman et al., 1998; Sircar, 2003; Yu et
al., 2002). These studies suggest that repeated administration of METH and PCP
produce neurological changes in the central nervous system in addition to behavioral
changes.
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Effects of Methamphetamine and PCP on Locomotor Activity: Acute and
Withdrawal Phases
Methamphetamine and Locomotor Activity. In adult rats, an acute injection of

methamphetamine (METH) enhances locomotor activity (Clemens et al., 2004;
Ohmori et al., 1995). However, METH effects on locomotor activity
(hyperlocomotion) vary depending on the dose. At a low dose (0.3-2.0 mg/kg),
METH enhances locomotion, whereas a moderate dose of METH (3.0-4.0 mg/kg)
increases locomotion and induces stereotypy (Gentry et al., 2004; Shoblock et al.,
2003). In developing rats, however, the acute effects of METH have not been tested.
However, findings from a previous study showed that the effects of amphetamine, a
similar psychostimulant, on locomotor activity vary depending on age. For example,
low to high doses of amphetamine (2-10 mg/kg) enhanced locomotor activity on
postnatal days (PD) 18-22, but the same doses failed to affect locomotion after PD
34-38 (Lanier & Isaacson, 1977). For older rats (PD 45-49) medium doses (2-5
mg/kg) enhanced locomotion, whereas a high dose (IO mg/kg) did not affect
locomotor activity (Lanier & Isaacson, 1977). Thus, given that METH and
amphetamine act on the central nervous system in a similar manner (Melega et al.,
1995), a prediction is that the acute effects of METH on locomotor activity may also
vary across different age groups. Although acute METH produces differential effects
on locomotion depending on the dose in adult rats, METH effects on locomotor
activity in developing rats are not clear.
During the withdrawal period, locomotor activity of METH-treated rats
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appears to be biphasic. Timar et al. (2003) reported that in adult rats, suppressed
locomotion was observed during the first 3 days of withdrawal, but not 7, 14, and 28
days after METII administration (10 mg/kg, 4 injections). However, Wallance et al.
(2001) found in adult rats a decrease in locomotion during 7-13 days after METII
injections using the same dose and frequency used in Timar et al's study (2003). In
Wallance et al 's study, locomotor activity was measured continuously for 24 hrs, and
locomotion was decreased during the diurnal period, but not during the nocturnal
period, suggesting that the time of behavioral testing contributes to METII effects on
locomotion.
In developing rats, METH effects on locomotor activity during the
withdrawal period appear to differ from those for adult rats. METII exposure during
PD 1-10 or PD 11-20 (30 mg/kg, two injections/day, 10 days) produced
hypolocomotion when tested on PD 60 (Vorhees et al., 1994) which corresponds to
30-50 days of withdrawal. These results suggest that exposure to METII during
development produce a prolonged effect on locomotion. Thus, although exposure to
high doses of METII appears to suppress locomotion during withdrawal periods in
both adult and developing rats, the impact of METII on behavior is greater on
developing rats than adult rats.

Neuroc/1emica/ Cl,ange Associated wit/, METH. METII-induced hyperlocomotion
is thought due to enhance dopamine (DA) and serotonin (5-HT) in the brain,
particularly in the nucleus accumbens (NAc). Microdialysis studies have indicated
that METII enhanced locomotion and also increased DA and 5-HT in the NAc
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(Shimada et al., 1996; Shoblock et al., 2003). This is consistent with the notion that
DA in the NAc mediates locomotor activity (Wise, 2000). Further evidence showed
that depletion of DA in the NAc inhibited hyperlocomotion induced by a dopamine
agonist, apomorphine (Liu et al., 1998). On the other hand, effects on 5-HT may
affect locomotion indirectly via the DA system. For example, direct infusion of 5HT IA agonist into the NAc potentiated hyperlocomotion induced by cocaine, a
dopamine agonist, while 5-HT IA agonist alone did not affect locomotion (Muller et al.,
2004). Thus, it appears that 5-HT may enhance locomotion by potentiation of
psychostimulants effects, thereby indirectly increasing DA in the NAc. Nevertheless,
enhanced DA and 5-HT following repeated METH is highly correlated with
hyperlocomotion seen in both adult and developing rats.

Phencyc/idine and Locomotor Activity. In adult rats, acute injection of phencyclidine
(PCP) produces hyperlocomotion, stereotypy, and ataxia in a dose dependent manner
(Sturgeon et al., 1979; Tani et al., 1994). In developing rats, PCP differentially affects
locomotor activity depending on the age. On postnatal day 10 (PD 10), a low dose of
PCP (1.5 mg/kg) enhanced locomotion, whereas a medium dose (3.0 mg/kg) failed to
produce hyperlocomotion (Pamela et al., 2000). During PD 21-60, the same doses of
PCP (1.5-3.0 mg/kg) increased locomotion in a dose dependent manner, with the
greatest magnitude of change in locomotion in PD 21 rats (Pamela et al., 2000).
Similarly, a low dose of PCP (1.0 mg/kg), compared to a moderate dose (4.0 mg/kg),
produced the greatest locomotion on PD 12, whereas a dose-dependent increase in
locomotion was found on PD 19 (Scalzo & Burge, 1994). Thus, unlike adult rats that
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showed enhanced locomotion in a dose dependent manner, there is a distinctively
different pattern in PCP effects on locomotion in developing rats. This pattern of
responsiveness to PCP varies across different postnatal days, with a more variable
pattern during early development and a less variable one during a later stage of
development.
During withdrawal, adult rats treated with PCP (20-30 mg/kg/day, 6 days)
showed a decrease in locomotor activity when tested 11 days after the last injection
(Sams-Dodd, 2004). In developing rats, daily injection of PCP (7.5 mg/kg, once/day,
16 days) during PD 24-39 produced long-lasting hypolocomotion, whereas the same
doses of PCP during PD 4-19 failed to affect locomotion (Scalzo, 1996). Thus, like
METH, PCP produces a distinctively different pattern of locomotion in developing
rats. This pattern of responsiveness to PCP varies across different postnatal days, with
smaller changes in locomotion during early development and greater changes during
later development.

Neurochemical Change Associated with PCP. PCP is a glutamate antagonist that
blocks N-methyl-D-aspartate (NMDA) receptors in the brain (Zukin & Javitt, 1993).
However, PCP-induced hyperlocomotion is thought to be due to enhanced dopamine
(DA) and glutamate in the mesolimbic system, which includes the nucleus accumbens
(NAc) and the prefrontal cortex (PFc). Direct infusion of PCP into the NAc produced
hyperlocomotion and increased DA in the NAc (McCullough & Salamone, 1992),
while depletion of DA in the NAc attenuated PCP-induced hyperlocomotion
(Steinpreis & Salamone, 1993). Similarly, direct infusions of PCP into the PFc
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produced locomotor enhancement, whereas neurotoxic lesions in the PFc attenuated
the PCP-induced hyperlocomotion (Jentsch et al., 1998). Although these reports
clearly suggest that PCP-induced hyperlocomotion is due to enhanced DA in the NAc
and the PFc, the mechanism by which PCP produces hyperlocomotion is not well
understood. One possible explanation is that PCP increases DA level in the NAc and
the PFc by blocking NMDA receptors in the GABAergic intemeurons within the
ventral tegmental area (VTA). The VTA sends a major dopamine projection to the
NAc and PF c. Thus, inhibition of inhibitory input to the VTA would lead to excitation
of the VTA, which in turn would increase release of DA in the NAc and PFc (Wise,
2000). An alternative explanation is that PCP enhances glutamate transmission in the
NAc and PFC, thereby producing hyperlocomotion. Microdialysis study showed a
glutamate increase in the NAc and PFc after PCP treatment (Barbara & Moghaddam,
1998), and blockade of non-NMDA glutamate receptors in the NAc and the PFc
inhibits PCP-induced hyperlocomotion without changing DA level (Takahata &
Moghaddam, 2003). Although these reports provide evidence for critical involvement
of glutamate in PCP-induced hyperlocomotion, it is unclear how PCP, a NMDA
receptor antagonist, enhances glutamate transmission in the NAC and PFc.
Nevertheless, enhanced levels of DA and glutamate within the mesolimbic system,
particularly, the NAc and the PFc, are closely associated with PCP-induced
hyperlocomotion.

Effects ofMethamphetamine and PCP on Social Interaction: Short-term
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Withdrawal Phase
In rats, social interaction is often defined by interaction between two 'unfamiliar' rats
in a neutral arena (File & Seth, 2002; Tonissaar et al., 2004). Social interaction is
typically measured by the time spent in active interaction, including sniffing,
following (chasing), or grooming the partner during behavioral testing (File & Seth,
2002; Tonissaar et al. 2004). Social interaction is frequently employed to test the
effect of pharmacological and surgical treatment on anxiety (See File & Seth, 2002).

Met/1amphetamine and Social Interaction. Previous studies have suggested that
amphetamine derivatives, such as METH and 3,4-methylenedioxymethamphetamine
(MDMA or ecstasy), affect social interaction (Clemens et al., 2004; McGregor et al.,
2003). In adult rats, only moderate doses (5 mg/kg, 4 injections) of METH, but not
low doses (2.5 mg/kg, 4 injections), decreased social interaction four weeks after
injections (Clemens et al., 2004). Similarly, exposure to an amphetamine derivative
during development appears to produce a long-lasting decrease in social interaction.
For example, rats exposed to MDMA on PD 39 decreased social interaction 12 days
after the last injection (Fone et al., 2002). Exposure to MDMA on PD28 also
produced a long-term decrease in social interaction when tested during adulthood, PD
84 (Bull et al., 2004). Thus, unlike locomotor activity, exposure to METH at different
stages of development would be expected to produce comparable deficits in social
behavior. Given the evidence that METH and MDMA produce neurotoxic effects on
the same brain regions (Armstrong & Noguchi, 2004), exposure to METH during the
developmental period would be expected to produce a prolonged decrease in social
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interaction.

Met!,amp/1etamine and Neural Structures Implicated in Social Interaction. The
prefrontal cortex (PFc) has been implicated in mediation of social interaction. In rats,
for example, the medial part of the prefrontal cortex is thought to mediate social
interaction by regulating fear- and anxiety-related behavior (Gonzalez et al., 2000).
Animal studies with PFc lesions, however, have yielded inconsistent results. For
example, bilateral lesions in the medial prefrontal cortex both increased fear response
(Gonzalez et al., 2004) and decreased fear response {Shah & Treit, 2003). According
to Rangel et al. (2003), PFc lesions produced an anxiolytic effect the second week
after the surgery, and they produced anxiogenic effect fifth week post-surgery,
suggesting that the state of anxiety depends on a progressive change in the prefrontal
cortex. Presumably, the behavioral shift from a 'less anxious state' to a more anxious
state' would be reflected in social interaction during the course of change in the
prefrontal cortex.
Repeated administration of high doses of METH produce neurotoxic effects
on dopaminergic and serotonergic axon terminals (Armstrong & Noguchi, 2004; Frost

& Cadet, 2000) and produce persistent depletion of DA and 5-HT in various brain
regions. In particular, neurotoxic doses of METH deplete DA in the striatum and the
PFc (Clemens et al., 2004; Wagner et al., 1980). Parallel studies have demonstrated
that neurotoxic doses of METH dep_lete 5-HT in the hippocampus, the PFc, the
striatum, and the amygdala (Armstrong & Noguchi, 2004; Daberkow et al., 2005;
Schroder et al., 2003; Wrona, et al., 1997). Given the evidence that reduction of 5-HT
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level in these brain regions was highly correlated with a long-term decrease in social
interaction following MDMA (ecstasy) administration (Mcgregor et al., 2005),
impaired social interaction appears rather specific to reduced 5-HT function in these
brain regions.
P/iencyclidine and Social Interaction. Few studies have investigated PCP effects on
social interaction in adult rats. To my knowledge no study has investigated PCP
effects on social interaction in developing rats. Sams-Dodd (1996, 1998) reported that
in adult rats, either single injections or continuous administration of PCP via mini
pumps reduced social interaction. One study examined the effect of PCP on social
interaction during the withdrawal period. According to Sams-Dodd (2004), social
interaction tested 10 days after PCP injection (5-30 mg/kg/day for 6 consecutive
days) at 3 months of age was not affected. Moreover, coadministration of a
neurotoxic dose of PCP (50 mg/kg, one or four injections) in conjunction with
pilocarpine, which promotes PCP-induced neurotoxicity, given at 4 months of age
also failed to affect social interaction which was tested on day 10 of withdrawal
(Sams-Dodd, 2004). Sams-Dodd's findings suggest that in adult rats social interaction
is affected by PCP acutely but restored during the withdrawal period. In developing
rats, the effects of PCP on social interaction during the withdrawal period are
unknown. Further studies are needed to examine the effect of PCP on social
interaction in developing rats.
P/iencyclidine and Neuronal Structures Implicated in Social Interaction. PCP, like
METH, produces neurotoxicity in the brain. A Single dose of PCP (5 mg/kg) changed

gene expression in the prefrontal cortex, and such change in expression of transcripts
was thought to be associated with the immediate toxic effects of PCP (Kaiser et al.,
2004). In adult rats, continuous infusion of PCP (5.45 mg/kg/day) across 5 days
increased glucose metabolism in the limbic system and cortical regions 24 hr and 10
days after the treatment (Elllison et al., 1996). These regions included the
hippocampus, the retrosplenial cortex, and the posterior cingulate cortex. The authors
hypothesized that the persistent increase in glucose metabolism in these structures
was due to widespread neurotoxicity during the withdrawal period. Thus, although
behavioral evidence with respect to changes in social interaction is insufficient, the
dysfunctional state of cortical and limbic structures, such as the hippocampus, may
impair social interaction.

Effects of Methamphetamine and PCP on Spatial Learning: Long-term
Withdrawal Phase
Methamphetamine and Spatial Learning. In adult rats, acute injection of neurotoxic
doses ofMETII produces long-term deficits in learning and memory. METH-treated
rats (four injections of 12.5 mg/kg at 2 hr interval) showed impaired learning when
they were tested in the spatial watermaze task 65 days after the treatment (Friedman
et al., 1998), suggesting that spatial learning was impaired by METII. More recent
reports indicate that METH injections (4 mg/kg, 4 injections at a 2 hr interval)
impaired short- and long-term memory in a novel object recognition task when testing
occurred 1 and 3 weeks after the treatment, without affecting the acquisition and
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retention of spatial information (Schroder et al., 2003). Similarly, following four days
of withdrawal, METH (three injections of 10 mg/kg at a 2 hr interval) produced a
selective memory deficit in the novel object recognition task, but not in the spatial
version of the recognition task, which involved simply moving the sample object to a
new location (Bisagna et al., 2002).
In developing rats, repeated administration of METH affects learning if it is
given within a specific period during development. According to Vorhees at al. (1994),
repeated injections ofneurotoxic doses of METH (30 mg/kg, twice/day, 10 days)
during PD 11-20 impaired the acquisition of a spatial water maze task tested on
approximately PD 50 (Vorhees et al., 1994). On the other hand, the same dose and
frequency of METH injections failed to affect acquisition if it was given during PD 110 (Vorhees et al., 1994), suggesting that exposure to METH during the later stage,
not the earlier stage, of development is d.etrimental to new learning. Subsequent
studies by the same group examined METH effects on learning using a lower dose
and a greater number of injections than those used in their previous study (I 0
mg/kg/day at 2 hr interval, 4 injections/day, 10 days). They found that METH
exposure during PD 11-20 impaired spatial and reversal learning when tested around
PD 50 (Vorhees et al., 2000). Interestingly, the same dose and frequency of METH
injections selectively impaired the acquisition of spatial reference memory and the
reversal task, without affecting spatial working memory (Williams et al., 2003a).
Moreover, when METH was given (10 mg/kg, 4 injections/day at a 2 hr interval, 10
days) during PD 11-15, performance in the spatial reference and reversal task was
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impaired, whereas METH given during PD 15-20 failed to have these effects
(Williams et al., 2003b). More recent study by the same group examined the effects of
METH on learning following exposure to different doses at various stages, PD 21-30
(2.5-10 mg/kg), PD 31-40 (1.25-7.5 mg/kg), PD 41-50 (1.25-5.0 mg/kg), and PD 5160 (1.25-5.0 mg/kg). The justification for using various doses was that rate depended
on developmental stage: the highest dose used in their previous reports (1 0mg/kg, 4
injections/day, 10 days) is known to produce toxicity. When the rats were tested in a
learning task in adulthood, only the rats exposed to METH during PD 41-50 showed
impaired spatial reference memory (Vorhees et al., 2005). These findings indicate that
during development there is a specific time-window when the nervous system is
sensitive and vulnerable to neurotoxic doses of METH. Clearly, exposure to METH at
specific developmental periods produces an enduring learning deficit in adulthood.

- P/1encyclidine and Spatial Learning. Previous studies have demonstrated that in
adult rats PCP and other non-competitive NMDA antagonists impair spatial learning
during the acute drug state, and that learning was restored during the early withdrawal
period (Campbell et al., 2004; Kesner & Dakis, 1993; Whishaw & Auer, 1989). Thus,
the effects of a brief exposure to PCP on learning are transient rather than long-term
in adult rats. On the other hand, chronic treatment with PCP impairs the acquisition of
cognitive tasks, particularly set-shifting in adult rats. When the rats were treated PCP
(5 mg/kg, 2 injections/day, 7 days) and tested after 7 days of withdrawal, PCP-treated
rats showed a retarded acquisition in reversal of a visual discrimination task. However,
the same animals showed normal acquisition in a novel visual discrimination
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(Jentisch & Taylor, 2001). The authors attributed the selective deficit in the reversal
learning to impairment in inhibitory control (Jentsch & Taylor, 2001). Thus, chronic
administration of PCP may impair flexibility in set-shifting, particularly intradimensional shift, where the discriminative stimuli in the same dimension are
switched (Dalley et al., 2004; Jentsch & Taylor 2001). Similarly, compared to
controls, PCP-treated rats (the same as those used in Jentisch & Taylor) required a
greater number of trials to reach a behavioral criterion when the rule was shifted
extra-dimensionally (Rodefer et al., 2005). Thus, chronic administration of PCP
appears to produce inflexibility in set-shifting when the discriminative stimuli in one
dimension (odor) are switched to the other (medium) (Rodefer et al., 2005). Thus, in
adult rats, chronic, but not acute, administration of PCP selectively affects the ability
to shift context-appropriate rules.
In developing rats, exposure to PCP during development produces a longlasting effect on spatial learning in young adulthood. Daily injection of PCP (5
mg/kg/day) during PD 5-15 disrupted the acquisition of spatial water maze task tested
on PD 35 and PD 60 (Sircar, 2003). In addition, rats treated with PCP (8.7 mg/kg) on
PD' 7, 9 and 11 showed an impaired acquisition of spatial reference, reversal and
working memory tasks tested in adulthood (Andersen & Pouzet, 2004). Thus, it
appears that early exposure to PCP produces profound effects on learning in
adulthood. Unlike METH, which required a time-window of sensitivity at a specific
developmental period to produce an enduring learning deficit, exposure to PCP from
as early as PD 5-10 produces enduring effects on cognitive behavior in adulthood.
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Rationale for METH and PCP Treatment on PD 50-51. Although previo~s studies

have indicated that exposure to MEIB and PCP during an early development
produces behavioral deficits (Sircar, 2003; Wallance et al., 2003b), the effects of
exposure to MEIB and PCP at a later developmental stage (PD 50-51) on a range of
behavior have not been investigated. According to Vorhees et al. (2005), MEIB
treatment during PD 41-50 impaired spatial learning tested in adulthood. To my
knowledge, no study has investigated the effects of PCP exposure during late
development and its long-term behavioral consequences. Given the evidence that
NMDA receptor antagonists, including PCP, begin to produce neurotoxicity in the
limbic structures on PD 45 (Farber et al. 1995; Farber, 2003), exposure to PCP after
PD45 would produce long-term behavioral deficits that are differentiated from the
other developmental stages.
MEIB and PCP also affect the dopaminergic system in the prefrontal cortex
and the striatum (Jentsh et al., I 998; Shoblock et al., 2003; White et al., 1995). Thus,
exposure to these drugs during development would affect development of the
dopaminergic system and lead to long-term behavioral deficits. In rats, the
dopaminergic systems mature during PD 40-60 by increasing the density of dopamine
receptors in the PFc and the striatum until PD 60 (Kalsbeek et al., 1988). In particular,
the density of prefrontal DA receptors peaks around PD 40-60 (Anderson et al., 2000),
whereas the density of DA receptors in the striatum peaked around PD 40 and
declined until PD 120 (Gelbard et al., 1989), suggesting that METH and PCP
exposure during later development would affect the dopaminergic system.
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Clearly, these studies indicate that exposure of METH and PCP during the late
development (PD 50-51) would affect both dopaminergic and glutamatergic systems
in the prefrontal cortex and the striatum during development, and exposure to these
drugs are likely to produce long-term behavioral deficits.

Specific Aims of the Thesis

The present study was aimed to investigate the acute and long-term effects of
exposure to high doses of METH and PCP on locomotor activity, social interaction,
and spatial and reversal learning. Juvenile rats (PD 50-5 I) were treated with METH
(9 mg/kg) or PCP (9 mg/kg), twice per day at a 12 hr interval for two consecutive
days. Locomotor activity was measured during acute and withdrawal periods (PD 5079), social interaction was measured during the withdrawal period (PD 54-79), and
spatial and reversal learning were tested in adulthood (PD 90 or older) (see Table. 1).
Hypotheses were: (1) Juvenile rats exposed to METH and PCP will increase
locomotor activity at the acute stage and decrease locomotor activity during the
withdrawal stage; (2) METH- and PCP-treated rats will decrease social interaction
during the withdrawal stage; (3) Rats exposed to METH and PCP during PD 50-51
will show deficits in spatial and reversal learning in adulthood.

Methods

Experiment 1. Effects of Methamphetamine and PCP on Locomotor Activity:

Table 1
Schedule of Treatment and Behavioral Measurement

~
BEHAVIOR
LOCOMOTOR
ACTIVITY
SOCIAL
INTERACTION
SPATIAL
LEARNING

ACUTE STATE

FIRST

SECOND
INJECTION

INJECTION

THIRD
INJECTION

WITHDRAWAL STATE

FOURTH
INJECTION

DAY3

.

-

-

DAY7

DAY14

LONG-TERM

DAY28

Short-term

Long-term

Short-term

Long-term

-

POSTNATAL DAY 90 or
older

.

.

--

Note. Locomotor activity, social interaction, and spatial learning were measured at different periods. The first
injection was on postnatal day 50. Locomotor activity was measured twice during the acute drug state, and four times
during withdrawal. Social interaction was measured 4 times during withdrawal. Spatial learning was measured after
animals reached adulthood, postnatal day 90 and after (long-term withdrawal). Arrows ( - - ) indicate behavioral
testing period.
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Acute Drug Phase and Withdrawal Phase
Subject
Thirty-two Wistar rats (postnatal day 30-79; 150-200 g at start of the experiment)
were used in this experiment and treated in accordance with NIH guideline. Rats were
housed in the Psychology Department Laboratory at Morehead State University under
a 12/12 light-dark cycle (10:00/22:00), and food and water were available ad libitum.
Rats were housed in gang cages (4 rats/cage) to maintain a comparable environment
to that of the social interaction experiment. All animals were handled for 5 min per
day for at least 3 days prior to the beginning of the experiment.
Apparatus
Locomotor activity was measured in an open-field arena, which contained four zones
in a square. A video camera mounted on the ceiling of the room and centered above
the field could monitor the activity of a subject in each zone of the field. Output from
the video camera was routed to a VCR, which sent the output to a computer. Realtime activity was shown on a monitor, and a video tracking system collected and
quantified locomotion, using the contrast between the light subject (rat) and the dark
background at a speed of 30 images/sec. Computer software analyzed distance
traveled every 5 min for a 60 min period. The room was illuminated by two standing
lights (150 Watts/ light) beside the open-field and one lamp (25 Watts) positioned
above the video camera.
Locomotor Activity
Animals were separated from the group and placed into one of four zones with the
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treatment conditions randomized. Locomotor activity was measured for a 60 min
period. After each session, animals were returned to their gang cage.
Drug Administration
On postnatal day (PD) 50-51, a total of four injections of METH (9.0 mg/kg, s.c.),
PCP (9.0 mg/kg, s.c.) or saline (0.9%, I ml/kg, s.c.) were administered at a 12-h
interval (8:00 am, 8:00 pm). Rats were divided into two groups: METH and PCP. In
the METH group (n = 16), two of four rats received METH injections, and the
remaining two received saline. Similarly, in the PCP group (n = 16), two of four rats
received PCP injections, and the remaining two received saline.
Experimental Design
One day prior to the first injection, animals were habituated to the open-field for 60
min. The acute effect of the treatment was measured immediately after the first (day
1) and the third (day 2) injection. The withdrawal effect of the treatment was
measured during a short-term (3 days and 7 days after the last injection, PD 54 and
58) and a long-term period (14 and 28 days after the last injection, PD 65 and 79).
Data Analysis
Locomotor activity of drug-treated vs. vehicle-treated rats was analyzed with twoway mixed ANOVA: separate analyses were done for acute (3 treatments x 2
sessions) and withdrawal effects (3 treatments x 4 sessions). In addition, each session
was further analyzed by two-way mixedANOVA (3 treatments x 12 five-min bins).
LSD procedure was employed for post hoc analysis. Vehicle-treated rats from the
METH and PCP groups were combined and treated as one vehicle group because
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two-way ANOVAs yielded no significant difference between two vehicle groups
during the acute and the withdrawal states. One vehicle animal was excluded from the
analysis due to a tracking problem.

Experiment 2: Effects of Methamphetamine and PCP on Social Interaction

Subjects
Fifty-six Wistar rats (PD 30-79) were used in this experiment. On PD 30, animals
were divided into groups of four (total 14 groups). Each subject in the group was
color coded using permanent markers: red for drug-treated through the dorsal surface,
black for saline control at the posterior part of the dorsal surface, green for one
vehicle control at the center part of the dorsal surface, and yellow for the other
vehicle control at the anterior part of the dorsal surface.

Social Interaction
Social interaction of four rats was measured in the open-field (4 rats/compartment).
The interaction was taped by a video camera mounted on the ceiling for a 60 min
period for off-line analysis. Social interaction was defined by two criteria: 1) active
approach to other rats and 2) turning the head toward another rat approximately 45
degrees or greater and touching the other rat's body. Specifically, the frequency and
the duration of each criterion were measured. The 60-min observation period was
divided into 7 segments (8 min/segment), excluding the first 2 min, which was a brief
habituation period in each session. During each segment (8 min), social interaction of
saline- and drug-treated rats was scored separately, by alternating 4 min intervals
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within each 8-min segment. Frequency of the criteria was ranked in a range of five (04): 0 = O; 1 = 1; 2-5 = 2; 6-13 = 3; > 13 = 4. Duration of the criteria was also ranked
in a range of five (0-4): 0 sec= O; 1-86 sec= 1; 87-159 sec =2; 160-239 sec= 3;
>239 sec = 4). This range of scoring system was based on a distribution of frequency
and duration of criteria every 25%. Social interaction score was obtained by
multiplying frequency and duration scores. An overall social interaction score was
obtained by adding the scores of 7 8-min segments. This scoring system is similar to
methods used in previous studies (White et al., 1998; Fone et al., 2002). Frequency of
contacts was positively skewed and duration of contacts was negatively skewed. The
distribution of multiplied scores (Frequency x Duration) yielded a standard normal
curve. Pearson correlation showed 96% intraobserver reliability in the frequency
measure and 99% intraobserver reliability in the duration measure.
Drug Administration
On postnatal days 50-51, a total of four injections of METH (9 mg/kg, s.c.), PCP (9
mg/kg, s.c.) or saline (0.9%, lml/kg, s.c.) were administered at a 12-h interval (8:00
am, 8:00 pm). Rats were divided into two groups: METH and PCP. In the METH
group (n = 28), two of four rats from a gang cage received treatment: one METH (n =
7), one saline (n = 7). The remaining two did not receive any treatment (n = 14).
Similarly, in the PCP group (n = 28), two of four rats from a gang cage received
treatment: one received PCP (n = 7), one received saline (n = 7). The remaining two
did not receive any treatment (n =14).
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Experimental Design

Animals were habituated to the open-field for 60 min prior to the experiments. Social
interaction was measured during the withdrawal period, on Day 3, 7, 14 and 28 after
the last injection.
Data Analysis

Social interaction of the METH group and the PCP group was analyzed separately.
Two-way mixed ANOVA (2 treatments x 4 sessions) was used to analyze social
interaction. Data were further analyzed by LSD post hoc analysis. One PCP-treated
animal was sick and was eliminated after the third injection (n = 6 per treatment in the
PCP group).

Experiment 3: Effects of Methamphetamine and PCP on Spatial Discrimination
and Reversal
Subjects

Thirty-four Wistar rats treated with METH (n=8), PCP (n=8), or saline (n=18) on PD
50-51 were used in adulthood (PD 90 and after) in this study. Rats were separated
from the group and housed in ingle cages. All animals were handled for 5 min per day
for 3 consecutive days. Food was restricted to keep a subject at least at 85% of its
original weight and to train rats on the learning task.
Apparatus

Eight operant chambers (29.4 cm W x 24.5 cm D x 29.4 cm H) were used in this
experiment. Each chamber was equipped with a house light, two retractable bars, two
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signal windows (red and yellow cues), a speaker, and a pellet dispenser located
between the levers. Each chamber was placed in a sound-attenuating box (75.95 cm
W x 51.45 cm D x 51.45 cm H).

Behavioral Tasks
Initially the animals were shaped to barpress in the operant chamber. Shaping
included three steps: hopper training, barpress training, and position-bias removal. In
hopper training, food reward was associated with the illuminated hopper. In barpress
training, animals were successively shaped to barpress: first, the animals were
rewarded when approaching the lever; then they had to put their paw on the lever;
finally, they received food only when they pressed lever. In position-bias removal,
animals were trained press both right and left levers equally often.
Following bar-press training, animals were trained in the spatial
discrimination task (SD), which required a barpress opposite to the cue location. For
example, an animal had to press a right lever in response to a left light cue regardless
of the color (red or yellow) (Fig. IA). The animals were given 2 sec to respond
following cue illumination, and the cue was turned off immediately after a correct or
incorrect response, or after 2 sec elapsed. Trial types were presented in a
pseudorandom fashion. An incorrect response produced a brief tone (95 dB, 500
msec) and terminated the trial. The inter-trial interval (IT!) was 8 sec. Premature
barpresses prior to the onset of the stimulus reset the trial. A training session was
terminated either when the animal consumed I 00 pellets (Noyes, 45 mg) or after 60
min elapsed. A computer collected the percent correct responses, response latencies

A

Spatial Discrimination Task

B

Spatial Reversal Task

1~0~1 ~0~1 ~0; 1 ~0~I 1;0~11~t 0~11 ; 0~11~ 0; 1
t

Correct Bar Press

Correct Ba r Press

Figure I. Spatial discrimination task and reversal task. Stimulus cue was presented either at right or left with two
different colors (red or yellow) at each trial. In spatial discrimination task (A), rats required a non-matching barpress
to the cue location. In reversal task (B), rats required a matching barpress to the cue location. The arrow indicates the
correct response.

N

w
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(correct and incorrect), and the number ofbarpresses during the ITI For acquisition, a
behavioral criterion (2:: 85% correct responses, three consecutive days) was used.
Reversal training began when the animal reached the behavioral criterion on
SD. In the spatial reversal task (SDR), a correct response was defined as a barpress
same as the cue location. Thus, the animals had to press a right lever in response to a
right stimulus cue, vice versa (Fig. 1B). The other conditions were exactly identical to
those for the SD, and the same variables were collected during the acquisition of SDR.
The behavioral criterion for acquisition of the reversal task was 2:: 85 % correct
responses for three consecutive days.
Drug Administration
Four injections ofmethamphetamine (9 mg/kg s.c.) or phencyclidine (9 mg/kg s.c.)
were administered on PD 50-51. Each injection was given every 12 hours (8:00 am,
8:00 pm). Control subjects received saline injections on the same schedule ..
Experimental Design
Animals were divided into two groups: METH (n = 8) and PCP (n = 8) with paired
vehicles (n = 9 in each group). The METH group was divided into two squads, and
each squad had four METH-treated and four saline-treated rats. Similarly, the PCP
group was divided into two squads with four PCP-treated and four saline-treated rats
in each squad. Two saline-treated rats were trained separately. In the first squad, drugtreated rats were assigned to chambers 1-4, and saline-treated rats were assigned to
chambers 5-8, whereas, in the second squad, drug-treated rats were assigned to
chambers 5-8 and saline-treated rats were assigned to chambers 1-4. Rats were
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trained in the task once a day. SD lasted until the animal reached the behavioral
criterion, whereas SDR lasted for 22 days.

Data Analysis
Statistical analyses were performed separately in the METH group and the PCP group.
Two-way mixedANOVA (2 treatments x 22 training sessions per task) was employed
to analyze the percent correct responses, response latencies (correct and incorrect),
and number ofbarpresses during the ITI. LSD pair-wise comparisons were performed
for further analyses. One-way between-subjectANOVA was used to analyze the
number of training days required to reach the criterion in each treatment group.
During the acquisition of SD, some rats reached the behavioral criterion in the earlier
training phase. Their training was terminated at that point because over-training in SD
could confound the acquisition of SDR. For the statistical analysis the missing values
for remaining sessions in SD were replaced with the value of the last session.

Results

Experiment 1: Methamphetamine and PCP on Locomotor Activity: Acute and
Withdrawal (short- and long-term)

Locomotor activity was measured twice during the acute drug state, immediately after
the first injection (PD 50) and the third injection (PD 51), and it was measured four
times during the withdrawal period: 3 days (PD 54), 7 days (PD 58), 14 days (PD 65)
and 28 days (PD 79). Overall locomotion during a 60 min session was compared
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among three treatments in acute (3 x 2 ANOVA) and withdrawal periods (3 x 4
ANOVA). Behavioral activity was further analyzed every 5 min across a 60 min
period (3 x 12ANOVA).
Acute Drug State. Immediately after the first injection, METH- and PCP-treated rats
showed enhanced locomotion compared to saline-treated rats. Immediately after the
third injection, however, METH-treated rats showed locomotor activity comparable to
that of saline-treated rats, whereas PCP-treated rats showed a further enhanced
locomotion (Fig. 2). A 3 x 2 ANOVA yielded a significant treatment effect [F (I, 28)
=

23.15,p < .001] and interaction between treatment and injection [F (2, 28) = 43.61,

p < .001], but not a significant effect of injection [F (1, 28) = 0.02,p > .05]. For the
first injection, the post hoc analysis revealed a significant difference between METH
and saline treatment [t (21) = 4.50,p < .001], and PCP and saline treatment [t (21) =
2.39,p < .05]. At the third injection, the post hoc analysis revealed a significant
difference between PCP and saline treatment [t (21) = 9.75,p < .001], but not METH
and saline treatment [t (21) = -0.35,p > .05].
Immediately after the first injection, METH-treated rats increased locomotor
activity during the initial 25 min period, whereas PCP-treated rats increased
locomotor activity during the last 25 min, compared with saline-treated rats (Fig. 3A).
Immediately after the third injection, METH-treated rats showed locomotor activity
comparable to that of saline-treated rats, whereas PCP-treated animals showed
enhanced locomotion throughout the 60 min period (Fig. 3B). A 3 x 12 AN OVA on
the first injection yielded a significant treatment effect [F (2, 28) = 10.53,p < .001],
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horizontal axis represents the order of injection. The vertical axis represents the distance traveled (cm) during the 60
min period. Error bars indicate standard error of the mean (SEM). Immediately after the first injection, both METH and
PCP enhanced locomotion. Immediately after the third injection, METH did not affect locomotor activity, while PCP
further enhanced locomotion. *p < .05.
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time passage effects [F (11,308) = 34.96,p < .001], and interaction between
treatment and time passage [F (22, 308) = 12.88,p < .001]. The following post hoc
pair-wise comparison revealed a significant difference between METI-I and saline
treatment for the initial 25 min and between PCP and saline treatment for the last 25
min (see Table. 2). A 3 x 12 ANOVA for the third injection yielded a significant
treatment effect [F (2, 28) = 55.53,p < .001], time passage effects [F (11, 308) =
43.67, p < .001], and interaction between treatment and time passage [F (22, 308) =
4.81,p < .001]. The following post hoc pair-wise comparison revealed a significant

difference between PCP and saline treatment throughout the 60 min period, whereas
METI-I and saline groups did not differ throughout the 60 min (see Table. 3).
Withdrawal State. During the withdrawal period, drug-treated rats (METH and PCP)

showed locomotor activity comparable to that of saline-treated rats (Fig. 4). Animals
across all the treatments increased locomotor activity as days progressed up to 14
days after the last injection. However, this tendency was not found 28 days after the
last injection. A 3 x 4 AN OVA yielded a significant effect of days after the last
injection [F (3, 84) = 10.75,p < .001], but did not show a significant treatment effect
[F (2, 28) = 0. 72, p > .05], and a significant interaction between treatment and days
[F (6, 84) = 1.81, p > .05].

On Day 3 after the last injection, METI-I-treated rats decreased locomotion
during the initial 5 min and increased locomotion between 25 and 30 min, compared
to saline-treated animals. On the other hand, PCP-treated rats showed locomotor
activity comparable to that of saline-treated rats (Fig. SA). On Days 7, 14, and 28
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Table 2

Effects of the First Injection ofMETH and PCP on Locomotor Activity
Time

5min

Treatment
METH

PCP
10min

METH
METH

15min

METH
METH

20min

METH
METH

25min

METH
METH

30min

METH
METH

35min

METH
METH

40min

METH
METH

45min

METH
METH

50min

METH
METH

55min

METH
METH

SO min

METH
METH

PCP
PCP
PCP
PCP
PCP
PCP
PCP
PCP
PCP
PCP

Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP

PCP

Vehicle
Vehicle

METH

PCP

Mean Diff

Std. Error

p-value

1256.62
172.03
1084.59
3718.16
358.42
3359.74
2710.41
425.76
2284.65
1610.32
264.16
1346.17
954.45
363.07
591.38
652.90
420.35
232.55
456.00
548.22
-92.21
384.83
734.79
-349.96
169.14
735.93
-566.80
39.47
773.67
-734.20
78.80
788.20
-709.39
-17.23
786.87
-804.10

373.83
373.83
426.94
518.83
518.83
592.54
485.68
485.68
554.69
461.82
461.82
527.44
336.19
336.19
383.96
348.47
348.47
397.98
285.60
285.60
326.18
235.18
235.18
268.60
202.81
202.81
231.63
151.41
151.41
172.93
153.09
153.09
174.84
152.63
152.63
174.32

p < .01
p> .05
p< .05
p < .001
p > .05
p < .001
p < .001
p > .05
p < .001
p < .01
p > .05
p < .05
p < .01
p > .05
p > .05
p> .05
p> .05
p> .05
p > .05
p> .05
p > .05
p> .05
p < .01
p > .05
p> .05
p < .01
p < .05
p> .05
p < .001
p < .001
p> .05
p < .001
p < .001
p> .05
p < .001
p < .001

Note. Pair-wise comparisons were done with LSD for 5-min bin.

t-value

3.36
0.46
2.54
7.17
0.69
5.67
5.58
0.88
4.12
3.49
0.57
2.55
2.84
1.08
1.54
1.87
1.21
0.58
1.60
1.92
-0.28
1.64
3.12
-1.30
0.83
3.63
-2.45
0.26
5.11
-4.25
0.51
5.15
-4.06
-0.11
5.16
-4.61
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Table 3

Effects of the Third Injection ofMETH and PCP on Locomotor Activity
Time

Smin

Treatment
METH

PCP
10min

METH
METH

15min

METH
METH

20min

METH
METH

25min

METH
METH

30min

METH
METH

35min

METH
METH

40min

METH
METH

45min

METH
METH

SO min

METH
METH

55min

METH
METH

60min

METH
METH

PCP
PCP
PCP
PCP
PCP
PCP
PCP
PCP
PCP
PCP

Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP
Vehicle
Vehicle

PCP

PCP

Vehicle
Vehicle

METH

PCP

Mean Diff

Std. Error

-336.04
1827.24
-2163.28
-354.30
1334.87
-1689.17
-132.26
1344.76
-1477.02
-29.51
1303.57
-1333.07
61.57
1435.15
-1373.58
87.22
1427.22
-1340.00
103.09
1634.03
-1530.94
127.28
1969.15
-1841.87
30.91
2177.70
-2146.79
-162.50
2295.62
-2458.12
-83.68
2350.44
-2434.12
-104.39
2692.02
-2796.42

387.64
387.64
442.71
349.46
349.46
399.11
240.95
240.95
275.18
246.15
246.15
281.13
205.48
205.48
234.67
187.93
187.93
214.63
172.33
172.33
196.82
172.19
172.19
196.66
218.22
218.22
249.22
234.51
234.51
267.83
244.03
244.03
278.70
234.11
234.11
267.38

p-value
p>
p<
p<
p>
p<
p<
p>
p<
p<
p>
p<
p<
p>
p<
p<
p>
p<
p<
p>
p<
p<
p>
p<
p<
p>
p<
p<
p>
p<
p<
p>
p<
p<
p>
p<
p<

.05
.001
.001
.05
.001
.001
.05
.001
.001
.05
.001
.001
.05
.001
.001
.05
.001
.001
.05
.001
.001
.05
.001
.001
.05
.001
.001
.05
.001
.001
.05
.001
.001
.05
.001
.001

Note. Pair-wise comparisons were done with LSD for 5-min bin.

t-value

-0.87
4.71
-4.89
-1.01
3.82
-4.23
-0.55
5.58
-5.37
-0.12
5.30
-4.74
0.30
6.98
-5.85
0.46
7.59
-6.24
0.60
9.48
-7.78
0.74
11.44
-9.37
0.14
9.98
-8.61
-0.69
9.79
-9.18
-0.34
9.63
-8.73
-0.45
11.50
-10.46

Short-term

20000

e
~

Long-term

15000

"ti
a,

iii
>

~

Ia,

-.
u

10000
fil METH

C

1/1

c

l§llPCP
□ Vehicle

5000

o
3 Days

7 Days

14 Days

28 Days

Days after Last Injection

Figure 4. Effects of methamphetamine (METH) and phencyclidine (PCP) on total locomotion (60 min) during
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Figure 5. Effects of methamphetamine (METH) and phencyclidine (PCP) on locomotor activity during withdrawal. The
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after the last injection, METI-I- and PCP-treated rats showed a locomotor activity
comparable to that of saline-treated rats throughout the 60 min period (Fig. SB, SC, 5
D). A 3 x 12 ANOVA on the locomotion 3 days after the last injection yielded a
significant interaction between treatment and time passage [F (22, 308) = 1.62, p

< .05] and a significant effect of time passage [F(ll, 308) = 67.09,p < .001], but did
not show a significant treatment effect [F (2, 28) = 0.32,p > .05]. Post hoc analysis
revealed significant differences between METI-I and saline treatment during the initial
5 min [t (21) = -2.68,p < .05], and between 25 and 30 min [t (21) = 3.31,p < .01]. A
3 x 12 ANOVA on the locomotion 7 days after the last injection showed a significant
effect of time passage [F(ll, 308) = 56.57,p < .001], but did not show a significant
treatment effect [F (2, 28) = 1.24, p > .05] or interaction between treatment and time
passage [F (22,308) = 0.54,p > .05]. Likewise, a 3 x 12ANOVA on the locomotion
14days after the last injection showed a significant effect of time passage [F (11, 308)

= 51.42,p < .001], but did not show a significant treatment effect [F (2, 28) = 2.71,p
> .05] or interaction between treatment and time passage [F(22, 308) = 1.17,p > .05].
A 3 x 12 ANOVA on the locomotion 28 days after the last injection yielded a
significant effect of time passage [F (11, 308) = 83.46,p < .001], but did not show a
significant treatment effect [F (2, 28) = 0.12, p > .05] or interaction between
treatment and time passage [F (22,308) = 0.59,p > .05].

Experiment 2: Methamphetamine and PCP on Social Interaction: Short- and
Long-term Withdrawal
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Social interactions were measured during the withdrawal period: 3 days (PD 54), 7
days (PD 58), 14 days (PD 65) and 28 days (PD 79) after the last injection. Each drug
treatment was compared with its paired vehicle, using 2 x 4 ANO VA to examine the
main effect of the treatment and the main effect of days after the last injection. The
withdrawal effects of PCP on initial 8 min of social interaction was also analyzed
with a 2 x 4 ANOVA, consistent with previous studies, which measured 10 min social
interaction (Sams-Dodd, 2004). Locomotor activity during the initial 8 min was also
analyzed to examine the involvement oflocomotor function on social interaction (2 x
4ANOVA).
METH-treated rats showed a gradual decrease in social interaction 7 days and
14 days after the last injection, while METH- and saline-treated rats showed
comparable social interaction 3 days and 28 days after the last injection (Fig. 6A)
Compared to saline-treated rats, METH-treated rats showed a significantly decreased
social interaction 14 days after the last injection. A 2 x 4 ANOVA yielded a significant
interaction between treatment and days after the last injection [F (3, 36) = 4.53, p

< .01], but did not show a significant treatment effect [F (1, 12) = 0.59,p > .05] or a
significant effect of days after the last injection [F (3, 36) = 0.50, p > .05]. The
following post-hoc analysis revealed a significant difference between METH and
saline treatment 14 days after the last injection [I (12) = -2.32,p = .038].
PCP- and saline-treated rats showed comparable total social interaction (60
min) during the withdrawal period (Fig. 7A). Rats in both treatments showed
decreased social interaction 14 days and 28 days after the last injection compared to
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their social interaction 3 days and 7 days after the last injection. However, PCPtreated rats showed a decreasing trend in the initial 8 min of social interaction
compared to saline-treated rats on Days 7, 14, and 28 of drug withdrawal (Fig. 7B).
This decreasing trend in social interaction was not due to impairment oflocomotor
activity because PCP- and saline-treated rats showed a comparable 8 min locomotion
during the withdrawal period. A 2 x 4 ANO VA on 60 min social interaction showed a
significant effect of days after the last injection [F (3, 30) = 8.44, p < .001 ], but did
not show a significant treatment effect [F (1 10) = 0.03, p > .05] or a significant
interaction between treatment and days after the last injection [F (3, 30) = 0.39, p

> .05]. Post hoc analysis revealed a significant difference in social interaction
between Day 3 and Day 14 [t (12) = 3.06,p < .05], 3 days and 28 days [t (12) = 4.69,

p < .001], 7 days and 14 days [t (12) = 2.56,p < .05] and 7 days and 28 days after the
last injection [t (12) = 3.72,p < .01]. A 2 x 4 ANO VA on the initial 8 min showed a
significant treatment effect [F (1, 10) = 5.65, p < .05], but did not show a significant
effect of days [F (3, 30) = 0.17, p > .05] and a significant interaction between
treatment and days after the last injection [F (1, 10) = 0.77,p > .05]. Pair-wise
comparisons did not show a significant difference between PCP and saline treatment
at any behavioral session, indicating that the significant treatment effect was due to
the accumulated difference between PCP and saline treatment across sessions. A 2 x 4
ANOVA on 8 min locomotor activity showed a significant effect of days after the last
injection [F (3, 63) = 2.93,p < .05]; however, the following post hoc analysis did not
reveal any significant differences among the comparisons. ANO VA did not show a
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significant treatment effect [F (I, 21) = 0.22,p > .05] or a significant interaction
between treatment and days after the last injection [F (3, 63) = 1.42,p > .05].

Experiment 3: Methamphetamine and PCP on Spatial Discrimination and
Reversal
To test the long-term effects of METH and PCP on spatial learning, acquisition of the
spatial discrimination (SD) and the reversal task (SDR) were studied. Acquisition of
SD, which required a barpresses opposite to the cue location, was assessed by percent
correct responses, response latencies (correct and incorrect), and number of
barpresses during the inter-trial intervals (ITI). In addition, number of days fo reach

,'

the behavioral criterion (> 85 % correct response for 3 consecutive days) was
measured. Once animals reached the behavioral criterion, acquisition of SDR, which
required a barpresses same as the cue location, was assessed with the same test
variables. Two-way and One-way ANOVA were used when appropriate. LSD pairwise comparisons were performed for further analyses.

Effects of METH on Spatial Discrimination

In spatial discrimination, both saline- and METH-treated rats showed a gradual
increase in the percent correct responses across training sessions (Fig. SA). A 2 x 22
ANOVAyielded a significant effect of training session [F (21,315) = 79.68,p < .001],
but not a significant treatment effect [F (1, 15) = 0.31, p > .05] nor a significant
interaction between treatment and training session [F (21, 315) = 0.60, p > .05].
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METH- and saline-treated rats required a similar number of training days to reach the
behavioral criterion (Fig. SB). One-way AN OVA did not yield a significant treatment
effect [F(l, 15) = 1.79,p > .05].
Correct response latency did not differ between METH- and saline-treated
rats. Rats in both treatments showed relatively stable correct response latencies across
the training sessions (Fig. 9A). A 2 x 22 ANOVAyielded a significant interaction
between treatment and training session [F (21, 315) = 1.87,p < .05]. According to the
post hoc analysis, the significant interaction was due to the_ slightly faster correct
response latency in METH-treated rats on Days 15 and 19, however, no other major
differences were observed. ANOVA did not show a significant treatment effect [F (1,
15) = 1.13,p > .05] or a significant effect of the training session [F (21, 315) = 1.44,

p> .05].
Incorrect response latency did not differ between METH- and saline-treated
rats. Saline-treated rats decreased incorrect response latencies across training sessions.
Similarly, METH-treated rats showed a decrease in incorrect response latencies
across training sessions (Fig. 9B). A 2 x 22 ANOVA yielded a significant effect of
training session [F (21, 315) = 12.94,p < .001], but not a significant treatment effect

[F (1, 15) = 0.34, p > .05] or a significant interaction between treatment and training
session [F (21, 315) = 0.46,p > .05].
METH- and Saline-treated rats showed a gradual decrease in number ofITI
barpresses during acquisition (Fig. 9C). A 2 x 22 AN OVA yielded a significant effect
oftraining session [F(21, 315) = 48.06,p < .001], but not a significant treatment
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effect [F (1, 15) = 0.36, p > .05] or a significant interaction between treatment and
training session [F (21, 315) = 0.92,p > .05].
Thus, METII- and saline-treated rats required a comparable number of
training days to acquire spatial discrimination and had similar pattern of percent
correct responses, response latencies, and number of barpress during the ITI across
the training sessions.

Effects ofMETH on Reversal
In the reversal task saline-treated rats gradually increased percent correct responses as
the training sessions progressed. METH-treated rats showed a slightly slower increase
in percent correct responses compared to saline-treated rats (Fig. 10A). A 2 x 22
ANOVA showed a trend toward a treatment effect [F (1, 15) = 3.30,p = 0.08] and a
significant effect of training session [F(21, 315) = 54.17,p < .001]. The interaction
between treatment and training session was not significant [F (21,315) = 0.61,p

> .05]. METII- and saline-treated rats required a similar number of training days to
reach the behavioral criterion (Fig. 1OB). One-way ANOVA did not yield a significant
treatment effect [F(l, 15) = 2.11,p > .05]. Although there were no significant
treatment effects in percent correct responses and days to criterion, METII-treated
rats showed a trend toward a slower increase in percent correct responses. Post hoc
pair-wise comparisons revealed significant differences between METII and saline
treatment on training session 6, 12, 18, 20, 21, and 22 (p < 0.05), indicating that
METII-treated rats showed a poor performance during reversal toward the end of the
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training session.
Correct response latency did not differ between METH- and saline-treated
rats. Saline-treated rats showed stable correct response latency across all the training
sessions. Similarly, METH-treated rats showed consistent correct response latencies
across all the training sessions (Fig. 1lA). Although a 2 x 22 ANOVA yielded a
significant effect of training session [F (21, 315) = 2.03, p < .01 ], the following post
hoc analysis did not show any difference among the possible comparisons. There was
no significant treatment effect [F (1, 15) = 0.01,p > .05] or a significant interaction
between treatment and training session [F (21,315) = 0.56,p > .05].
Incorrect response latency did not differ between METH- and saline-treated
rats. Saline-treated rats gradually decreased incorrect response latency across the
training sessions. Similarly, METH-treated rats showed a gradual decrease in
incorrect response latency across the training session (Fig. 1IB). A 2 x 22 AN OVA
yielded a significant effect of training session [F (21,315) = 8.17, p < .001] but did
not show a significant treatment effect [F (1, 15) = 0.05, p > .05] or a significant
interaction between treatment and training session [F (21,315) = 0.80 p > .05].
Saline-treated rats gradually decreased the number ofbarpresses during the
ITI across the training sessions. Similarly, METH-treated rats showed a gradual
decrease in number of barpresses during the ITI across the training session (Fig. 11 C).
A 2 x 22 ANO VA showed a significant effect of training session [F (21, 315) = 9.60,

p < .001], but did not show a significant treatment effect [F (1, 15) = 0.49,p > .05] or
a significant interaction between treatment and training session [F (21, 315) = 0.32, p
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> .05].
Thus, METH- and saline-treated rats took a comparable number of training
days to acquire SDR and were similar in terms of response latencies and the number
ofbarpresses during the ITI across the training sessions. However, during reversal
METH-treated rats showed a trend toward a slower increase in percent correct
responses toward the end of the training session.

Effects ofPCP on Spatial Discrimination
In the spatial discrimination task saline-treated rats gradually increased percent
correct responses as training progressed. Similarly, PCP-treated rats showed a gradual
increase in the percent correct responses with training (Fig. 12A). A 2 x 22 AN OVA
yielded a significant effect of the training session [F (21, 315) = 113.74, p < .001], but
did not show a significant treatment effect [F (1, 15) = 1.44, p > .05] or a significant
interaction between treatment and training session [F (21, 315) = 1.08, p > .05].
PCP- and saline-treated rats required a similar number of training days to reach the
behavioral criterion (Fig. 12B). One-way ANOVA did not yield a significant
treatment effect [F (1, 15) = 1.31, p > .05].
Correct response latency did not differ between PCP- and saline-treated rats.
Saline-treated rats showed stable correct response latencies across the training session.
Similarly, PCP-treated rats showed consistent correct response latencies across the
training session (Fig 13A). Although a 2 x 22 ANOVA yielded a significant effect of
the training sessions [F (21, 315) = 2.35,p < .01], this was due to the slightly faster
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correct response latency on Day 3 of the training session, and no other significant
differences were obtained in the post hoc analysis. There were no significant
treatment effect [F (1, 15) = 0.08,p > .05] or a significant interaction between
treatment and training session [F (21,315) = 0.48,p > .05].
Incorrect response latency did not differ between PCP- and saline-treated rats.
Saline-treated rats decreased incorrect response latencies across the training sessions.
Similarly, PCP-treated rats showed a decrease in incorrect response latencies across
the training sessions (Fig. 13B). A 2 x 22 ANO VA yielded a significant effect of
training session [F (21, 315) = 21.31,p < .001], but did not show a significant
treatment effect [F (1, 15) = 1.51,p > .05], or a significant interaction between
treatment and training session [F (21, 315) = 0.48, p > .05].
Saline-treated rats gradually decreased the number ofbarpresses during the
ITI across the training sessions. Similarly, PCP-treated rats showed a gradual
decrease in number ofbarpresses during the ITI (Fig 13C). A 2 x 22 ANO VA yielded
a significant effect of training session [F (21,315) = 69.01,p < .001], but did not
show a significant treatment effect [F (!, 15) = 0.05,p > .05] or a significant
interaction between treatment and training session [F(21, 315) = 1.33,p > .05].
Thus, PCP- and saline-treated rats required comparable number of training
days to acquire SD with similar transitions in the percent correct responses, response
latencies, and number of barpress during ITI across the training session.

Effects ofPCP on Reversal
Saline-treated rats increased percent correct responses during the earlier training
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sessions, and remained at asymptote during the remaining sessions. On the other hand,
PCP-treated rats showed a slower increase in the percent correct responses compared
to saline-treated rats (Fig. 14A). A 2 x 22 AN OVA yielded a significant treatment
effect [F (I, 15) = 4.54,p < .05], and the following post hoc analysis revealed a
significant difference between PCP and saline treatment on Days 6, 10, 12, 15, 18 and
20 of the training sessions. ANOVA also showed a significant effect of the training
session [F (21, 315) = 117.94,p < .001] but not a significant interaction between
treatment and training session [F(21, 315) = 0.69,p > .05]. Compared to salinetreated rats, PCP-treated rats required more training days to reach the behavioral
criterion (Fig. 14B). One-way ANOVA showed a significant treatment effect on days
to reach the behavioral criterion [F(l, 15) = 6.53,p < .05].
Correct response latency did not differ between PCP- and saline-treated rats.
Saline-treated rats showed stable correct response latency across the training session.
Similarly, PCP-treated rats showed constant correct response latency across the
training session (Fig. !SA). A 2 x 22 AN OVA did not yield a significant treatment
effect [F (I, 15) = 1.67,p > .05], a significant effect of training session [F (21, 315) =
1.22, p > .05] and a significant interaction between treatment and training session [F
(21,315) = 1.38,p > .05].
Incorrect response latency did not differ between PCP- and saline-treated rats.
Saline-treated rats decreased incorrect response latency across the training session.
Similarly, PCP-treated rats showed a decrease in the incorrect response latency across
the training session (Fig. 15B). A 2 x 22 ANOVA yielded a significant
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effect of the training session [F (21,315) = 7.82,p < .001], but did not show a
significant treatment effect [F (1, 15) = 0.57,p > .05] and a significant interaction
between treatment and training session [F (21,315) = 0.66,p > .05].
Saline-treated rats decreased number ofbarpresses during ITI across the
training session. Although PCP-treated rats also showed a decrease in number of
barpresses across the training session, these animals showed a greater number of barpress during the earlier phase of the training session compared to saline-tre11ted
animals (Fig. 15C). A 2 x 22 ANO VA yielded a significant treatment effect [F (1, 15)

= 5.93,p < .05], a significant effect of the training session [F (21,315) = 58.54,p
< .001] and a significant interaction between treatment and training session [F (21,
315) = 3.89,p < .001]. Post hoc analysis revealed a significant difference between
PCP and saline treatment on Days 1, 2, 3, 5, 6, and 19 of the training sessions.
Thus, compared to saline-treated rats, PCP-treated rats required a greater
number of days to acquire SDR and had a slower increase in the percent correct
responses. In addition, PCP-treated rats showed a greater number ofbarpresses during
the ITI in the earlier training phase in comparison with saline-treated animals. PCPand saline-treated rats showed comparable changes in response latencies across the
training sessions.

Discussion

Effects of Methampbetamine and Pbencyclidine on Locomotor Activity
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Acute Drug State. METH and PCP differentially affected locomotor activity after
the first and the third injections. Following the first METH injection locomotor
activity was markedly enhanced during the first half of the session, whereas the third
injection did not affect locomotion. On the other hand, the first PCP injection
enhanced locomotion during the second half of the session, whereas the third PCP
injection enhanced locomotion throughout the entire session. Acute effects of METH
and PCP are further discussed below.
Enhanced locomotion (hyperlocomotion) following the first METH injection
peaked during the first 10 min after the injection and lasted for 25 min. This initial
behavioral excitation may reflect changes in dopamine transmission in the nucleus
accumbens, which is thought to regulate locomotor activity (Tran et al., 2004). Thus,
decreased locomotor activity during the second half of the session may reflect some
change of DA in the nucleus accumbens. Shoblock et al. (2003) found that METH
exponentially increased DA in the NAc 20 - 40 min after the injection (2 mg/kg, i.p.).
The time course of DA increase in the NAc seen in Shoblock et al's study is similar to
a decrease in locomotion seen in the present study. This is likely due to dose
differences: 9 mg/kg (present study) vs. 2mg/kg (Shoblock et al, 2003). Interestingly,
the third METH injection did not affect locomotor activity. This lack oflocomotion is
probably due to the cumulative METH in the system from the second injection, which
in turn promoted further DA increase in the nucleus accumbens following the third
injection. In fact, Brooks et al. (2004) showed that a single injection of a moderate
dose (3 mg/kg) of METH produced hyperlocomotion, which lasted 300 min (5 hrs),
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while lower doses (0.3 - 1 mg/kg) produced hyperlocomotion for 100-200 min,
respectively. In the present study a relatively high dose (9 mg/kg) of METH was
injected at 12 hr intervals. Thus, the residual effects from previous injections in
addition to the third injection produced excessive DA in the nucleus accumbens,
leading to a decrease in locomotion. Moreover, this biphasic pattern of locomotor
activity in the present data is consistent with previous reports that a single injection of
low vs. high doses of METH produced different locomotor patterns. For example, a
single injection oflow doses (1-2 mg/kg) of METH produced continuous
hyperlocomotion (Mori et al., 2004; Shoblock et al., 2003), whereas moderate to high
doses of METH (3-20 mg/kg) enhanced locomotion briefly, followed by a decrease in
locomotion (Brooks et al., 2004; Mori et al., 2004; Shoblock et al., 2003). Thus, the
present data suggest that the pattern of locomotor activity depends on the dose and
frequency of METH injection. Given that METH increases DA in the NAc (Shoblock
et al., 2003), the present findings also indicate that although enhanced dopamine in
the nucleus accumbens is required to produce hyperlocomotion, changes in locomotor
activity are sensitive to a moderate, but not an excessive increase in DA.
PCP produced opposite effects to that of METH on locomotor activity. The
first PCP injection did not affect locomotion during the first half of the session.
However, PCP increased locomotion during the second half of the session. The
delayed onset of increase in locomotion may be due to the indirect effect of PCP on
DA transmission in the NAc. PCP is known to block the PCP-site ofNMDA receptors
(Zukin & Javitt, 1993) and is implicated in an increase in extracellular DA
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concentration in the NAc (Hanson et al., 1995), indicating the indirect action of PCP.

In fact, Nishijima et al. (1996) reported that PCP increased DA level in the striatum
20-40 min after the PCP injection (2.5-10 mg/kg, i.p.). The time course of DA
increase in the striatum in Nishijima et al's study corresponds to the onset of
hyperlocomotion in the present study. Thus, the delayed onset of hyperlocomotion
may reflect the indirect action of PCP on the DA increase in the NAc. Locomotor
excitation during the second half of the session may have been due to the moderate
increase of DA in the NAc. Unlike METI-I, which produces prolonged
hyperlocomotion at only at low doses (Shoblock et al. 2003), PCP (2.5 - 10mg/kg)
enhances locomotion in a dose-dependent manner (Tani et al, 1994). Moreover,
METI-I (4.8 mg/kg) augmented peak DA in the NAc nearly fivefold compared to PCP
(10 mg/kg) (Shimada, et al. 1996). These data indicate that PCP moderately increases
DA in the NAc and produces hyperlocomotion. Interestingly, the third PCP injection
further increased locomotor activity throughout the session. One explanation for the
further increase in locomotion after the third PCP injection is that a carryover effect
from the previous two injections combined with the third injection, and further
increased DA level in the NAc. Nevertheless, hyperlocomotion continued to rise
throughout the session, indicating an indirect DA increase in the NAc. It is also
possible that locomotor activity was sensitized by the previous two injections.
Locomotor sensitization produced by the third PCP injection (3.2 mg/kg at 24 hr
interval) was also reported in a previous study (Xu & Domino, 1993).
Taken together, although METH and PCP affected locomotor activity, each
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drug produced distinctively different effects on locomotion. The first METH injection
markedly increased locomotor activity during the first half of the session, whereas the
third injection did not affect locomotion. On the other hand, the first PCP injection
produced hyperlocomotion during the second half of the session, whereas the third
injection enhanced locomotion throughout the entire session. This difference is
probably due to the different action of METH and PCP on the NAc. METH directly
affects the NAc and increases DA excessively, whereas PCP indirectly affects the
NAc and increases DA moderately. The acute effects of METH and PCP on
locomotor activity in the present study suggest that locomotor activity is sensitive to a
moderate increase of DA in the NAc but not an excessive increase.
Withdrawal State (Short- and Long-term). With an exception of withdrawal Day

3, both METH and PCP produced similar effects on locomotor activity during shortand long-term withdrawal periods, which spanned Days 3- 28 from the last drug
injections.
Three days after the last METH injection, the METH group showed slightly
suppressed locomotion during the first 5 min only, compared to the control. Since rats
tend to get engaged in exploratory behavior at the beginning of the testing period, a
decrease in distance traveled during the first 5 min period may reflect a locomotor
deficit. Timar et al. (2003) measured locomotor activity in a novel environment and
found a decrease in locomotion 3 days after METH (10 mg/kg, s.c. x 4 injections at a
2 hr interval). Although in Timar et al 's study locomotor activity was tested without a
habituation session (i.e. novel environment), their results are in agreement with the
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present study. In the present study, well-habituated rats also showed a decrease in
locomotion 3 days after injections. It is possible that this hypolocomotion during the
first 5 min reflects DA depletion in the NAc. In fact, METH (5 mg/kg, s.c. x 5 daily
injection) increased the sensitivity of neurons in the NAc 5 days after the
administration (Amano, et al. 1996). Locomotor activity was not affected 7-28 days
post injections of METH in the present study. Previous study also reported
normalized locomotor activity at the same testing period (Timar et al. 2003).
Moreover, Amano et al. ( 1996) reported normal neuronal activity in the NAc 10 days
post administration of METH. This normalized locomotion 7-28 days post injections
may reflect the normal level of DA in the NAc.
PCP produced no effects on locomotor activity during acute- or long-term
withdrawal periods. While the present data indicate that PCP affects locomotion only
during the acute state, previous reports indicated that repeated treatment with PCP
produced a prolonged hypersensitivity. For example, following PCP treatment (20
mg/kg/day x 5 days), a challenge dose of PCP (3.2 mg/kg, i.p.) produced sensitization
during withdrawal periods 3 and 8 days after the PCP injection (Hanania et al., 1999).
The authors suggested that repeated PCP treatment produced a prolonged
hypersensitivity, possibly due to altered neurotransmitter systems (Hanania et al.,
1999). These findings are inconsistent with findings in the present study. One
explanation is that the dose of PCP used in Hanania et al's study is nearly three-folds
higher than the dose used in the present study, thereby producing a greater degree of
neurotoxicity. According to Bella et al. (2003), sensitivity of DA receptors in the
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prefrontal cortex was restored 4 days after withdrawal from PCP treatment (15
mg/kg/day for 2 weeks). Though Bella et al's study investigated the withdrawal effect
only 4 days after the treatment, it is highly likely that DA level in the prefrontal
cortex was recovered 3 days after the treatment, the time at which locomotor activity
was tested in the present study.
Taken together, the present data indicate that locomotor activity is severely
affected immediately after METH (9.0 mg/kg x 4 times) or PCP (9.0 mg/kg x 4 times).
During the withdrawal phase, however, locomotor activity of drug-treated rats
appears to return to that of the controls rather quickly. This recovery of the locomotor
activity appears to reflect the normalization of DA level in the mesolimbic system;
nevertheless, METH appeared to affect locomotor activity 3 days after the treatment,
probably depleting DA in the NAc.

Effects of Methamphetamine and Phencyclidine on Social Interaction
METH and PCP differentially affected social interaction during the withdrawal
periods: Days 3-7 (short-term) and Days 14-28 (long-term) of withdrawal. METHtreated rats showed a gradual decrease in social interaction on days 7 and 14 of
withdrawal. On the other hand, PCP-treated rats showed no overall change in social
interaction, except during the first 8 min observation period when they showed a
decrease in social interaction across Days 7-28, with a greater decrease on Day 14.
Further details of these drug effects are described below.
METH-treated rats showed comparable social interaction to that of saline-
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treated rats during withdrawal Day 3. However, METH rats gradually decreased
social interaction on Days 7 and 14, with a significant decrease on Day 14, and a
return to the same level as control on Day 28. However, this is inconsistent with the
previous finding that in adult rats, PCP decreased social interaction when tested 4
weeks after the last injection (Clemens et al., 2003). This difference may be due to the
age and familiarity of the subjects. Developing rats with the same partners were used
in the present study, whereas adult rats with different partners were used at each
testing period in the previous study.
An interesting finding is that METH-treated rats gradually decreased social
interaction on Day 7 and 14, with a significant decrease on Day 14, and returned to
the same level as control on Day 28. Such recovery of social interaction during longterm withdrawal may reflect a transient change in neurotransmitter systems, possibly
dopaminergic and serotonergic systems. In fact, change in the mesolimbic
dopaminergic system, which consists of the nucleus accurnbens (NAc), the prefrontal
cortex (PFc), and the ventral tegmental area (VTA), has been implicated in regulation
of social interaction (Tucci et al., 2000). In adult rats, dopamine was released from
the VTA to the PFc and NAc while the animals were engaged in social interaction
(Zhang et al., 1994), whereas loss of DA in the PFc decreased social interaction
(Clemens et al., 2004; Espejo, 2003). These data indicate that enhanced dopamine in
the mesolimbic system plays an important role in social interaction. In the present
study, METH-treated animals showed a gradual decrease of social interaction on days
7 and 14 after the last injection. It is conceivable that such gradual decrease in social
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interaction on Day 7 and 14 followed by recovery of social interaction on Day 28
may reflect a transient change in the mesolimbic system during short- and long-term
withdrawal periods.

An alternative hypothesis emphasizes METH effects on the serotonergic
system in the hippocampus (HIP), which may regulate anxiety. Social interaction has
been frequently used to measure the effects of anxiolytic or anxiogenic drugs, with
the assumption that a decrease in social interaction represents a state of high anxiety
(File & Seth, 2002). Thus, it is reasonable to speculate about possible effects of
METH on 5-HT and subsequent anxiety-related behaviors. For example, animals fed
a tryptophan (a precursor of 5-HT)-depleted diet showed increased anxiety-related
behaviors by spending more time in the corner of the openfield and by the wall, and
such behavioral changes were correlated with decreased tryptophan in the HIP
(Blokland et al., 2002). Similarly, in adult rats, pretreatment with 5-HT agonist into
the HIP prevented anxiety-related behaviors (Kagamiishi et al., 2003). Although these
findings provide strong support for the involvement of 5-HT in the anxiety-induced
decrease in social interaction, there is a methodological complication. In these studies
adult rats were paired with an unfamiliar partner at the time of testing, and their
interaction was measured. In the present study, however, developing rats were raised
in gang cages for 50 days (PD30-PD80, 4 rats/cage), during which time METH was
administered and social interaction was measured. It is reasonable to assume that
anxiety level due to encounter of new rats would be certainly higher than that due to
interaction with familiar rats. Nevertheless, a possible role of reduced hippocampal 5-
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HT in the gradual decrease in social interaction following METH treatment has not
been ruled out.
Overall social interaction of PCP-treated rats was comparable to that of salinetreated rats throughout the withdrawal periods. However, PCP-treated rats showed a
decrease in social interaction during the initial 8 min on Day 7, Dayl4, and Day 28 of
withdrawal. Lack of PCP effects on overall social interaction is consistent with the
findings of Sams-Dodd (2004) that in adult rats PCP failed to affect social interaction
10 days after the last treatment (Sams-Dodd, 2004). In an earlier study, Sams-Dodd
(1996) reported that PCP decreased social interaction during the initial 10 min period

in adult rats. The fact that locomotor activity was not affected on Day 7, Day 14, and
Day 28 (see earlier discussion on Experiment 1) argues against the possibility of that
the initial decrease in contact was caused by motor dysfunction. The present findings
from juvenile rats and Sams-Dodd's report from adult rats indicate a similar change in
social behavior during initial contacts. It is conceivable that a brief decrease in social
contacts may be due to a social withdrawal effect of PCP.
PCP treatment in adulthood failed to affect social interaction in Sams-Dodd's
study (2003), whereas PCP treatment during PD 50-51 produced a decreasing trend
in social interaction in the present study. This discrepancy may be due to the age of
the animals. According to Farber et al. (1995), sensitivity to the neurotoxic effects of
NMDA antagonists in the limbic systems begins on approximately PD 45 and
increases until PD 90-120. One explanation for the present findings is that NMDA
blockade at PD 50-51 could have affected another neurotransmitter system, possibly

64

a dopaminergic system. In fact, exposure to NMDA blockade (1.25-5 mg/kg) in the
early developmental period (PD1-PD21) altered the dopaminergic system in the PFc

in adulthood (Wedzony et al., 2005). Given the evidence that the DA in the PFc plays
an important role in social interaction (Clemens et al., 2004; Espejo, 2003), exposure
to PCP during development may produce an enduring effect on social interaction by
altering DA level in the PFc.
Decreased social interaction following PCP may be partly due to
dysfunctional circuitry within the limbic system, particularly between the HIP and
PFc. For example, PCP produces neural degeneration in the HIP (Ellison & Switzer
1993; Elllison et al., 1996) and neonatal lesions in the HIP decreased social
interaction after maturation, while lesions in the PFC alone did not decrease social
interaction (Flores, et al. 2005a), indicating that the pathway from the HIP to the PFc,
but not from the PFC to HIP, mediates social interaction. This is consistent with the
findings that the lesions in the HIP produced morphological change in the NAc and
the PFc (Flores, et al. 2005b), and that simulation of the HIP increased DA in the NAc
(Legault, et al. 2000; Floresco et al. 2001). Given the anatomical evidence that the
NAc and PFc receive inputs from the HIP (Carr & Sesack, 1996; French & Totterdell,
2002), PCP may exert its effects by disrupting HIP function, which, in turn, affects
the NAc and PFc, thereby decreasing social interaction.
Taken together, METH and PCP produced differential effects on so'~ial
interaction during withdrawal periods. METH gradually decreased social interaction
on days 7 and 14 after the last injection, while PCP decreased social interaction for an
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initial 8 min during withdrawal periods. During withdrawal periods, METH appears
to affect the mesolimbic system directly, while PCP appears to affect the mesolimbic
system indirectly through the HIP. Differential effects of METH and PCP on social
interaction during withdrawal periods may be due to the differential drug effects on
different neurotransmitter systems and their interaction with the mesolimbic system.

Effect of Methamphetamine and PCP on Spatial Discrimination and Spatial
Reversal

Effects of METH on Spatial Discrimination and Reversal Rats treated with METH
during PD 50-51 showed comparable performance on the spatial discrimination task,
compared to that of the saline-treated rats when they were tested in adulthood (after
PD 90). When these METH-treated rats were trained in a subsequent spatial reversal
task, they showed a trend toward acquisition. Further details regarding the effects of
METH on spatial discrimination are discussed below.
In the spatial discrimination task (SD), both METH- and saline-treated rats
showed comparable performance, measured by the percent correct responses,
response latencies, the number ofbarpresses during the inter-trial interval (ITI), and
the number of days to reach behavioral criterion (?. 85 %, 3 sessions). During
acquisition of SD, control and METH-treated animals took a similar number of
sessions to reach a behavioral criterion and had a steady increase in the percent
correct response, consistent correct response latency, a decrease in the incorrect
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response latency, and a decrease in barpresses during the ITI. METH-treated rats
showed no impairment that would reflect a long-term deficit in spatial learning, motor
function, attention, or perseveration during acquisition of SD. Given that training on
the SD began approximately 40 days after the last METH injection, the present
findings indicate that there was no METH effect on SD. The present study is in
agreement with a previous report that exposure to METH (5 mg/kg, 4 injections/day
for IO days) during PD 51-60 did not affect acquisition of a spatial water maze task
30 days after the last injection (Vorhees et al. 2005). Interestingly, however, METH
(6.25 mg/kg/day, 4 injections/day for 10 days) given during PD 41-50 did impair
acquisition of the spatial water maze task (Vorhees et al. 2005), suggesting that there
is a time-window of sensitivity for METH effects. If this is the case, lack of METH
effects on acquisition of the SD in the present study can be ascribed to METH
treatment during a noncritical period during development. Nevertheless, the present
findings suggest that exposure during development did not affect SD in adulthood.
In the subsequent reversal task (SDR), however, METH-treated rats tended to
show a slower acquisition compared to saline-treated rats, especially toward the end
of the training session. METH- and saline-treated rats showed similarities in response
latencies, the number ofbarpresses during the ITI, and days to reach behavioral
criterion. These results suggest that METH tended to decrease the accuracy in
reversal learning, without producing motor deficits, attention deficits, or
perseveration. The present study is inconsistent with the previous report that exposure
to METH (5 mg/kg, 4 injections/day for 10 days) during PD 51-60 did not impair
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reversal learning tested 30 days post injection (Vorhees et al. 2005). Given the
comparability of the withdrawal periods used in the studies, the trend toward slowed
reversal in the present study, but not in Vorhees et al. (2005) may be due to a
difference in the tasks. In the reversal phase of the water maze task, animals were
required to swim to the opposite side of the platform within 2 min per trial (Vorhees
et al. 2005). During the reversal phase of the spatial discrimination task, animals were
required to make the opposite barpress within 2 sec, demanding a greater ability to
discriminate and to make correct responses within a short period of time. Thus, the
reversal task employed in the present study may be more sensitive to the cognitive
impairment.
A slow trend in acquisition of reversal task in METH-treated rats may be due
to the dysfunctional state of the striatum and the medial prefrontal cortex. Recent
study has suggested that in rats neurological changes in the striatum and the medial
prefrontal cortex were closely associated with behavioral deficits during reversal
learning (Daberkow et al. 2005; Kadota & Kadota, 2004). This is consistent with
previous reports that the medial prefrontal cortex mediates reversal learning (Lacroix
et al. 2002; Salazar et al. 2004). In particular, using the paradigm of the spatial
discrimination tasks in the present study, Salazar et al. (2004) found that rats damaged
in the medial prefrontal cortex showed a slower acquisition in the reversal task,
without affecting initial acquisition of spatial discrimination. Taken together, in the
present study, a slower learning seen in METH-treated rats during reversal may
primarily reflect dysfunctional state of the medial pre frontal cortex.
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Effects ofPCP on Spatial Discrimination and Reversal During the spatial
discrimination task, PCP- and saline-treated rats showed a similar pattern of
acquisition. During the reversal task, however, PCP-treated rats showed a retarded
acquisition compared to the saline-treated rats. Further details are discussed below.
In the spatial discrimination task (SD), both saline- and PCP-treated rats had
similar performance measures, including percent correct responses, response latencies,
the number ofbarpresses during the inter-trial interval (ITI), and the number of days
to reach a criterion (%CR;::,: 85%, 3 sessions). Across the training sessions, PCP- and
saline-treated rats showed a steady increase in correct responses per session, and the
groups showed no difference in the mean number of days required to reach a
behavioral criterion. PCP- and saline-treated rats showed stable correct response
latencies and a decrease in incorrect response latencies during acquisition of SD,
indicating that there is no change in gross motor function. Moreover, both treatment
groups showed a steady decrease in barpresses during the ITI, suggesting that PCPtreated rats did not exhibit 'impulsive' or 'disinhibitory' barpress responses during the
course of SD acquisition. Thus, the present findings provide evidence that exposure to
PCP (9 mg/kg, 12-hr interval, 4 injections) on PD 50-51 did not impair acquisition of
spatial discrimination. This is in agreement with previous reports that in adult rats
PCP and other similar non-competitive NMDA antagonists impaired spatial learning
at acute and earlier withdrawal, but not over long-lasting, periods (Campbell et al.,
2004; Kesner & Dakis, 1993; Whishaw & Auer, 1989). Such lack of effects on
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learning during the withdrawal period is consistent with findings that in adult rats,
PCP (5 mg/kg/day, 2 injections/day, 7 days) failed to affect acquisition of visual
discrimination in the T-maze (Jentsch & Taylor, 2001) as well as odor and tactile
discrimination after 10 days of withdrawal (Rodefer et al., 2005). However;' it should
be noted that PCP and MK-801, another non-competitive NMDA antagonist,
impaired spatial learning during the acute drug phase and the early (Day 4)
withdrawal period (Campbell et al., 2004; Kesner & Dakis, 1993; Whishaw & Auer,
1989).
Although the present findings from developing rats and previous findings
from adult rats indicate that exposure (brief or long-term) to PCP does not affect
acquisition of spatial discrimination, these findings are not in agreement with other
reports, showing that PCP treatment during an earlier developmental period produces
a long-lasting effect on spatial learning. For example, Sircar (2003) reported that
exposure to PCP (5 mg/kg, once/day, 11 days) during development PD 5-15 impaired
the acquisition of a spatial water maze task when the animals were tested in adulthood.
Similarly, PCP (8.7 mg/kg, once/day, 3 days) treatment on PD 7, 9, and 11 produced a
retarded acquisition of the spatial water maze task in adulthood (Wang et al. 2001 ).
One explanation for such discrepancies between the present findings and Sircar's
findings is that the age of the rats and the duration of the treatments differed: Sircar
(2003) used PD 5-15 and PD 11 treatment days, whereas PD 50-51 and 2 treatment
days were used in the present study. Thus, the present study gave evidence that PCP
administered during the late developmental period does not affect spatial and
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discriminative learning in adulthood.
In a subsequent reversal task (SDR), PCP-treated rats showed a
characteristically different pattern of acquisition from that of saline-treated rats: They
had a lower number of correct responses (i.e., a greater number of incorrect
responses) and a greater number ofbarpresses during the ITI, particularly during the
first half of acquisition, thereby yielding a retarded acquisition and requiring more
days to reach a behavioral criterion (%CR >85%, 3 sessions). Both treatment groups
showed similar patterns in other behavioral measures: stable correct response
latencies and a decrease in the incorrect response latencies during acquisition of SDR,
again indicating that there was no change in gross motor function. The difference did
not seem to be due to a difference in motivational state because during the earlier
stage of reversal PCP-treated rats tended to omit responding on a fewer number of
trials (data not shown). Thus, the present findings provide evidence that exposure to
PCP (9 mg/kg, 12-hr interval, 4 injections) on PD 50-51 selectively impaired reversal
learning (SDR) without affecting the ability to learn a new task (SD).
Previous studies have indicated that PCP treatment affects the ability to inhibit
the previously learned response. For example, Jentsch & Taylor (2001) reported that
PCP (5 mg/kg, 2 injections/day, 7 days) impaired reversal learning in a visual
discrimination task after 7 days of withdrawal. Interestingly, however, PCP did not
affect the acquisition ofa novel visual discrimination (Jentsch et al. 2001), suggesting
that acquisition of a new task was not affected. These results are consistent with
findings in the present study that exposure to PCP during PD 50-51 selectively
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impaired reversal learning in adulthood, without affecting spatial discrimination.
Neurochemical and neuroanatomical changes produced by PCP may be
responsible for enduring impairment in reversal learning in adulthood. According to
Sircar (2003), rats receiving PCP on PD 5-15 showed upregulated NMDA receptors
in the HIP and the frontal cortex in adulthood, suggesting that PCP treatment during
early development produces long-lasting effects on spatial learning and spatial
working memory in adulthood. Consistent with this notion, PCP on PD 7, 9 and 11
induced apoptosis in the frontal and olfactory cortices (Wang et al. 2001 ). Thus,
exposure to PCP during early development would produce long-term impairment in
spatial learning by producing neurochemical and neuroanatomical changes in the
brain. Nevertheless, PCP treatment during later development and in adulthood fails to
produce the same effect.
One line of evidence indicates that in adult rats blocking NMDA receptors in
the HIP reliably impairs spatial learning (Kesner & Dakis, 1995; Kesner & Dakis,
1996). Microinjections of PCP or MK-801, NMDA antagonists, directly into the HIP
disrupted spatial learning. Presumably, NMDA selectively impaired long-term
memory by disrupting the corisolidation process, while leaving short-term memory
intact (Kesner & Dakis, 1995; Kesner & Dakis, 1996). These studies examined only
the acute phase, and no long-term deficit in spatial learning was measured. Some
studies have demonstrated that brief and chronic exposure to high doses of PCP
produce neural degeneration in the limbic system, particularly the hippocampus (HIP),
the retrosplenial cortex, and the posterior cingulate cortex (Ellison & Switzer 1993;
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Elllison et al., 1996). Although PCP-induced behavioral deficits in the present study
may reflect a dysfunctional state of the HIP in adulthood, the more pronounced deficit
during the first half of reversal may reflect a transient dysfunction of the HIP. Perhaps
previous reports of a lack of the long-lasting effect of PCP and other NMDA
antagonists on spatial and discrimination learning (Jentsch & Taylor, 2001; Rodefer et
al., 2005; Whishaw & Auer, 1989) are due not only to different behavioral measures
and time of behavioral testing, but also due to differences in doses and frequency of
administration, and the age of the rats. Also, enduring effects of PCP on learning in
adulthood may depend on doses and frequency of administration during development.
Thus, PCP-induced neurotoxic effects in the brain may be rather mild and transient,
and thus insufficient to produce long-term effects on spatial learning in adulthood.
PCP-treated rats increased ITI barpresses during the first half of reversal
(SDR). Interestingly, however, enhanced ITI barpressing was not observed during SD.
In rats, the medial part of the prefrontal cortex (PFc) is thought to mediate reversal
learning (Bussey et al. 1997). Excitotoxic lesions in the PFc produced retarded
acquisition of a reversal task with impulsive responses occurring during the earlier
phase of training session, yet the same animals showed normal acquisition of a spatial
discrimination task using a visual stimulus (Salazar et al. 2004). Enhanced IT!
barpresses may have reflected prefrontal dysfunction, particularly during reversal.
This is consistent with the notion that repeated administration of PCP impairs ruleshift learning by damaging the dopaminergic system in the PFc (Jentsch & Taylor,
2001 ). Behavioral deficits in Salazar et al's study were similar to the present findings
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that PCP-treated rats showed a selective impairment in reversal learning. However,
PCP-induced deficits were due to dysfunction of PFc or HIP cannot be determined
based on the present findings. Nevertheless, it is likely that PCP impairs the ability to
shift rules, possibly by disrupting functions of the PFc.
Using brief exposure to PCP in development, the present study demonstrated a
long-term deficit in reversal learning in adulthood. This may reflect the susceptibility
of specific brain regions, such as PFc or/and HIP to PCP, as well as susceptibility of
specific neurotransmitter systems, such as dopamine, during a critical period in
development. Although it is inconclusive as to when such a critical period begins and
ends, a few studies have demonstrated that NMDA antagonists begin to produce
neurotoxicity in the limbic system approximately PD 45 and that toxicity increases
until PD 90-120 (Farber et al. 1995; Farber, 2003). PCP administrations as well as
learning tests were conducted in the present study during this time (PD90-I 20).
Chronic NMDA antagonist (CGP 40116) administration over a 20 day period (PD 121) altered dopaminergic function in the PFc on PD 60 by reducing tyrosine
hydroxylase by nearly 99% at the terminals in the PFc (Wedzony et al., 2005).
Neuroanatomical studies have demonstrated that during development, dopaminergic
fibers in the PFc increased in density through PD 20-60 and stops after PD 60
(Kalsbeek et al. 1988). Again, PCP treatment in the present study overlapped period
between the onset of susceptibility to neurotoxicity and the last stage of the
dopaminergic development (PD 45 and PD 60). Although, reversibility of the
cognitive dysfunction induced by PCP is unknown (Jentsch et al., 2001), one would
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predict that PCP treatment during this critical period may have produced irreversible
effects on the dopaminergic neurons in the PFc, thereby producing long-term
behavioral deficits in adulthood. One would also predict that the magnitude of the
behavioral deficits would depend on the dose and frequency of PCP administration
during this period.

General Discussion

The present study examined the effects of METH and PCP, given on PD 50-51 on
locomotor activity, social interaction, and spatial and reversal learning. The findings
in the present study indicate that the effects of METH and PCP on behavior differ
depending on the complexity of the behavior as well as on the time of behavioral
testing. METH and PCP affect behavior differently during the acute drug state as well
as chronically. The present study focused on behavioral changes observed during the
withdrawal period.
Clearly, METH and PCP affected locomotor activity during the acute drug
state. An interesting finding was the way in which these drugs affected locomotion
over time. The effects of acute METH on locomotor activity were characterized by a
brief hyperlocomotion, followed by a sharp decrease in locomotion. After repeated
administration, METH failed to affect locomotion during the acute drug state. Acute
PCP effects on locomotor activity differed from acute METH effects. There was a
steady increase in locomotion following acute PCP injection. After repeated
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administration, a same dose of PCP further enhanced locomotion during acute drug
state. Thus, with repeated administration, METH and PCP produced opposing effects
on locomotion during the acute drug state. The differential behavioral changes
immediately after METH and PCP are probably due to the different
pharmacodynamics of each drug, particularly their action at target sites.
Drug effects on behavior were expected to become subtler during the
withdrawal period (short- and long-term) compared to the acute drug state. Indeed,
locomotor activity was not affected after 3 days of withdrawal. Although drug effects
are rather subtle, difference in drug-induced behavioral changes appeared to linger
after 14 days of withdrawal and last nearly 2 months after the last injection. During
withdrawal Day 3, for example, social behavior of METH- or PCP-treated rats did not
differ from that of control rats. On Day 7, however, drug-treated rats showed a
decreasing trend in social interaction, compared to saline-treated rats that showed an
increasing trend. By Day 14, overall social interaction differed between METH- and
saline-treated rats: the METH group had a significant decline on withdrawal Day 14,
while the control group had an increase. Such contrast in social interaction between
METH-treated and control rats was not evident on Day 28. While the overall deficit
in social interaction produced by METH was distinct, overall social interaction of
PCP-treated rats was comparable to that of control rats. However, PCP-treated rats
showed a decrease in their initial social interaction (8 min) on Days 7, 14 and 28.
Such subtle deficits during an initial social encounter may reflect change in emotional
state, such as anxiety.
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The effects of METI-I and PCP on spatial learning differed, depending on the
nature of the spatial task. Neither METI-I nor PCP affected spatial discrimination.
During the spatial reversal task (SDR), however, METI-I-treated rats tended to show a
slower acquisition of reversal, whereas PCP-treated rats showed a significantly
impaired acquisition. Moreover, PCP-treated rats showed a high rate of barpress
during the ITI, particularly during the early reversal phase. Thus, METI-I and PCP
appear to produce characteristically different behavioral deficits during reversal.
It should be noted that testing of METH and PCP on spatial learning began
after 4 weeks of withdrawal and lasted for 6 weeks, spanning a total of 10 weeks of
withdrawal. , Comparing the present findings with other studies is rather difficult due
to methodological differences, such as dose and frequency of drug injections, testing
paradigm, and age of the rats. It is, however, reasonable to conclude that exposure to
METH and PCP during later development produced differential effects on behaviors
during the acute and withdrawal phases. Further studies on the distinctive changes
produced by METI-I and PCP given at various developmental stages are warranted.
In summary, the present study provide strong evidence that brief exposure to
METI-I and PCP during development acutely affects motor behavior and produces
withdrawal effects on social behavior as well as enduring effects on complex learning.
Exposure to METI-I and PCP affects higher order learning in adulthood. These
changes were not detectable when a simpler behavioral measure, such as locomotor
activity, was used~ During development, the brain structures that mediate simple to
higher functions undergo changes, and possibly have different sensitivities to METI-I
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and PCP, yielding differential behavioral changes. During a critical period, the brain
structures that mediate higher functions may be extremely vulnerable to
neurochemical changes. Brief exposure to drugs, such as METH and PCP, during a
critical period in development would produce profound change in these brain regions
and produce enduring effects on higher cognitive function in adulthood.
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